drugset / Trial / NCT04902183
Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19
Phase 2
Unknown
90 enrolled
Athens Medical Society
Elpen Pharmaceutical Co. Inc. · collabOBCTCD24 Ltd · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a phase II randomized, single-blind dose study to evaluate the safety and efficacy of exosomes overexpressing CD24 of two doses, Dose 1 - 10\^9 exosome particles (per dose) versus Dose 2 - 10\^10 exosome particles (per dose), to prevent clinical deterioration in patients with Moderate or Severe COVID-19 infection.
Timeline
- Start
- 2021-06-09
- Primary completion
- 2021-09-01
- Completion
- 2021-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CovenD24 | Other / unclassified | 1e+09 unknown | Inhaled |
| Subject | CovenD24 | Other / unclassified | 1e+10 unknown | Inhaled |